These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24471305)

  • 1. [Technical specifications for post-marketing pharmacoeconomic evaluation of Chinese medicine (draft version for comments)].
    Xie YM; Wang X; Wang N; Chang YP
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2925-9. PubMed ID: 24471305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation.
    Wang X; Wang ZF; Xie YM; Zhang W; Liao X; Chang YP;
    Chin J Integr Med; 2015 Jun; 21(6):473-80. PubMed ID: 24671571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
    Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
    Zhang W; Xie YM; Yu WY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expert consensus post-marketing evaluation scheme to detect immunotoxicity of Chinese medicine in clinical populations (draft version for comments)].
    Xie YM; Zhao YB; Jiang JJ; Chang YP; Zhang W; Shen H; Lu PF
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2933-6. PubMed ID: 24471307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Guidelines for economic evaluation of post-marketing Chinese patent medicine].
    Shi LW; Xie YM; Nie XY; Han S; Tian X; Wang ZF
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1129-1136. PubMed ID: 38621920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of Markov model in post-marketing pharmacoeconomic evaluation of traditional Chinese medicine].
    Wang X; Su X; Sun W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2844-7. PubMed ID: 22292381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice].
    Shang HC; Zhang BL; Li YP
    Zhong Xi Yi Jie He Xue Bao; 2008 Sep; 6(9):887-90. PubMed ID: 18782528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Illumination of pharmacoeconomics on Chinese herbal medicine inject].
    Zhang F; Zhou CF
    Zhongguo Zhong Yao Za Zhi; 2007 Mar; 32(5):453-6. PubMed ID: 17511156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Post-marketing clinical study of traditional Chinese medicine--lessons learned from comprehensive evaluation of Fufang Zaoren capsule].
    Qing S; Gao L; Zhang L; Jia JP; Liu XM; Ji SL; Yang XH
    Zhongguo Zhong Yao Za Zhi; 2013 Nov; 38(21):3790-4. PubMed ID: 24494575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Technical specifications for rational clinical use of parenterally administered Chinese medicine (draft version for comments)].
    Xie YM; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Zhao YB
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2930-2. PubMed ID: 24471306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Technical specifications for hospital-based intensive monitoring of post-marketing Chinese patent medicine].
    Xie YM; Liao X; Jiang JJ; Zhang YL; Ma R; Zhu MJ; Zhan SY; Liu JP; Liu J; Wen ZH; Yang ZQ; He Y; Li XL
    Zhongguo Zhong Yao Za Zhi; 2019 Jul; 44(14):2896-2901. PubMed ID: 31602831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Technical specification for re-evaluation of post-marketing clinical effectiveness of traditional Chinese medicine (first draft)].
    Zhao Y; Yang YY; Wang YX; Yang HM; Wu SX
    Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3211-3215. PubMed ID: 30200720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thought on several problems of clinical revaluation of post-marketing herb research].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(12):1641-3. PubMed ID: 20815225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Establishment of model of traditional Chinese medicine injections post-marketing safety monitoring].
    Guo XE; Zhao YB; Xie YM; Zhao LC; Li YF; Hao Z
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2974-8. PubMed ID: 24471314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A discussion of key issues on postmarketing reevaluation of Chinese medicine].
    Xie Y; Tian F
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1494-7. PubMed ID: 20822029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Process and key points of clinical literature evaluation of post-marketing traditional Chinese medicine].
    Liu H; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2848-50. PubMed ID: 22292382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Overview of pharmacoeconomic studies on traditional Chinese medicines and western medicines in treatment of stroke].
    Chang YP; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2012 Dec; 37(23):3509-12. PubMed ID: 23477129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establish research model of post-marketing clinical safety evaluation for Chinese patent medicine].
    Zheng WK; Liu Z; Lei X; Tian R; Zheng R; Li N; Ren JT; Du XX; Shang HC
    Zhongguo Zhong Yao Za Zhi; 2015 Sep; 40(18):3693-6. PubMed ID: 26983223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Post-marketing reevaluation for potential quality risk and quality control in clinical application of traditional Chinese medicines].
    Li HJ; He LY; Liu BY
    Zhongguo Zhong Yao Za Zhi; 2015 Jun; 40(12):2461-3. PubMed ID: 26591543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.